Caladrius Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Caladrius Biosciences, Inc.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
The CEO of US-based Caladrius Biosciences believes its share price will rise at least tenfold over the next three years as the cell therapy specialist’s pipeline advances to commercialization.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Amorcyte, Inc.
- California Stem Cell Inc
- NeoStem, Inc.